CRAMS
Industry
The
Contract Research and
Manufacturing Services
(CRAMS) Industry pertains to outsourcing services
and products from low-cost providers with World
class standards, in line with International
regulatory norms like the US FDA, Australian-TGA, UK
MCA and EMEA.
Traditionally, the pharmaceutical MNCs have been
outsourcing
intermediates,
active
pharmaceutical
ingredients
(APIs)
and
formulations.
Since
late
1990s,
CRAMS
has
gained
more
importance,
as |
|
MNCs have had a greater need to outsource due to
the pressure of maintaining their profitability.Outsourcing is gradually moving from being just a
tactical or opportunistic option to a more strategic
one to sustain the demand from markets moving into
the generic phase.
CRAMS in India has gained considerable momentum and
is estimated to be churning revenues of $850 million
annually. Over the last 5 years,
CRAMS industry has
been contributing close to 8 percent to the total
Indian pharmaceutical business. It is expected to
grow at a CAGR of over 25 percent from 2006 to 2011
due to the increasing number of chronic diseases and
combination of diseases characteristic of developing
and developed countries, as well as a number of
other factors.
Keeping this in mind, ALPL has a
strong orientation to research and development.
ALPL plans to undergo numerous research
and development initiatives that will enable us to
deliver newer products to our customers in a
cost-effective and timely manner. |
